發(fā)布時(shí)間：2018-06-26 11:11

  本文選題：玻璃體內(nèi)注射雷珠單抗 + 黃斑變性��； 參考：《中國老年學(xué)雜志》2014年23期

【摘要】：目的探討玻璃體內(nèi)注射雷珠單抗治療老年黃斑變性合并視網(wǎng)膜中央靜脈阻塞的療效。方法將2012年1月至2013年9月該院收治的老年黃斑變性合并視網(wǎng)膜中央靜脈阻塞患者62例62眼隨機(jī)分為觀察組和對照組,每組31例31眼。對照組接受視網(wǎng)膜光凝治療。觀察組每月玻璃體內(nèi)注射雷珠單抗0.5 mg,1次/月,連續(xù)治療3個(gè)月。統(tǒng)計(jì)分析兩組治療期間和治療后半年內(nèi)的最佳矯正視力、眼壓、黃斑中心凹厚度(CMT)、眼底熒光血管造影(FFA)黃斑區(qū)熒光滲漏和并發(fā)癥發(fā)生情況。結(jié)果觀察組治療前最佳矯正視力為3.32±0.58,低于治療1、2 w、1、2、3個(gè)月及治療后1、3、6個(gè)月的3.58±0.67,3.65±0.62,3.68±0.66,3.71±0.95,3.76±0.73,3.79±0.75,3.80±0.77和3.81±0.65;對照組治療1、2、3個(gè)月及治療后1、3、6個(gè)月的最佳矯正視力亦高于治療前,且治療2個(gè)月和3個(gè)月及治療后1、3、6個(gè)月觀察組最佳矯正視力均高于對照組;治療2 w內(nèi)兩組患者的眼壓出現(xiàn)升高后逐漸下降和CMT變薄,且治療2個(gè)月和3個(gè)月及治療后1、3、6個(gè)月觀察組眼壓均低于對照組,CMT亦較對照組薄(P0.05)。兩組治療后FFA黃斑區(qū)熒光滲漏情況均得以改善,且觀察組無明顯滲漏的患者比例較對照組升高(P0.05)。兩組結(jié)膜下出血、視網(wǎng)膜脫離、細(xì)菌性眼炎等并發(fā)癥的總發(fā)生率均為9.38%,兩者無差異(P0.05)。結(jié)論玻璃體內(nèi)注射雷珠單抗治療老年黃斑變性合并視網(wǎng)膜中央靜脈阻塞可有效提高患者視力、控制眼壓、促進(jìn)黃斑消退和視網(wǎng)膜出血的吸收且不會(huì)明顯增加并發(fā)癥的發(fā)生,具有良好的可行性和安全性,值得推廣用。
[Abstract]:Objective to evaluate the efficacy of intravitreal injection of Lei Zhu McAb in the treatment of senile macular degeneration with central retinal vein occlusion. Methods from January 2012 to September 2013, 62 cases (62 eyes) of senile macular degeneration complicated with central retinal vein occlusion were randomly divided into observation group (n = 31) and control group (n = 31). The control group was treated with retinal photocoagulation. In the observation group, intravitreous injection of 0.5 mg / month of Leizhu McAb was performed once a month for 3 months. The best corrected visual acuity intraocular pressure (IOP) central foveal thickness (CMT) fundus fluorescein angiography (FFA) macular leakage and complications were analyzed statistically. Results the best corrected visual acuity before treatment in the observation group was 3.32 鹵0.58, which was lower than that in the control group, which was lower than that in the control group at 1 w2, 3 months and 1 day after treatment, and the best corrected visual acuity in the control group was also higher than that in the control group at 1 month, 3 months and 1 month after treatment, and the best corrected visual acuity in the control group was also higher than that in the control group at 1 month, 3 months and 1 month after treatment, and the best corrected visual acuity in the observation group was 3.58 鹵0.67 鹵0.67 鹵0.76 鹵0.753.79 鹵0.753.80 鹵0.77 and 3.81 鹵0.65 respectively. The best corrected visual acuity (BCVA) in the observation group was higher than that in the control group after 2 months and 3 months and 1 and 6 months after treatment, and the IOP of the two groups gradually decreased and the CMT thinned after 2 weeks of treatment. The IOP of the observation group was lower than that of the control group at 2 and 3 months and 1 and 6 months after treatment (P0.05). The fluorescence leakage in the macular area of FFA was improved in both groups after treatment, and the proportion of patients without obvious leakage in the observation group was higher than that in the control group (P0.05). The total incidence of complications such as subconjunctival hemorrhage, retinal detachment and bacterial ophthalmitis was 9.38 in the two groups, and there was no difference between the two groups (P0.05). Conclusion intravitreal injection of Lei Zhu McAb in the treatment of senile macular degeneration with central retinal vein occlusion can effectively improve the visual acuity, control intraocular pressure, promote the absorption of macular regression and retinal hemorrhage without significantly increasing the incidence of complications. It has good feasibility and safety, and is worth popularizing.
【作者單位】： 南陽市中心醫(yī)院眼科;
【分類號】：R774.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前8條

1 田君;方凱;秦雪英;陳卿;李娟;于文貞;侯婧;陳大方;胡永華;黎曉新;;年齡相關(guān)性黃斑變性危險(xiǎn)因素的病例對照研究[J];北京大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2012年04期

2 馬樂;閆少芳;黃e，

本文編號：2070195